- Biomerica reported net sales of **$5.3 million** for the fiscal year ended May 31, 2025, a slight decrease from **$5.4 million** in the prior year, primarily due to global tariff-related uncertainties and a shift in product mix.  **[73290_cb4e7b569cdd48c1918889bf427a2e3f_0]** 
- The company significantly improved its financial efficiency, reducing operating expenses by over **$1.3 million** and improving its operating loss to **$5.1 million** from **$6.4 million** year-over-year.  **[73290_cb4e7b569cdd48c1918889bf427a2e3f_0]**  Cash used in operating activities also improved to **$3.8 million** from **$5.3 million** in the prior year.  **[73290_cb4e7b569cdd48c1918889bf427a2e3f_0]** 
- Key strategic advancements include the American Medical Association issuing a Proprietary Laboratory Analyses (PLA) code for Biomerica’s inFoods® IBS test, advancing its reimbursement pathway, and the introduction of a new patient self-collection system for inFoods® IBS to expand access.  **[73290_cb4e7b569cdd48c1918889bf427a2e3f_0]** **[73290_cb4e7b569cdd48c1918889bf427a2e3f_1]**

BIOMERICA (BMRA)